sapropterin
sapropterin: sourced relationships with 1 company · 2 clinical trials tracked · 3 FDA decisions.
sapropterin evidence translation
What we can confirm
3 FDA records · 2 tracked trials
What it means
What to watch
Prepared research question
How could sapropterin → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2021-03-30 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
Rhode Island Diastolic Dysfunction - Heart Failure
Primary endpoint: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise
Pilot Study to Assess Impact of Kuvan® Supplementation as an Adjunct Treatment in Subjects With Dominantly-inherited GTPCH Deficiency on Mood, Behavioral and Motor Phenotypes
Primary endpoint: Change in BH4 Levels in Cerebral Spinal Fluid
FDA Decisions3 records
Frequently asked questions
Which companies have sourced relationships with sapropterin?
sapropterin has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve sapropterin?
BioSniper tracks 2 clinical trials involving sapropterin.
What is sapropterin's latest FDA decision?
The most recent tracked FDA decision for sapropterin is Approval, dated May 13, 2022.